Jing Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jing Chen has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Likun Chen
State Key Laboratory of Oncology in South China, Guangzhou, China
28 shared publications - Chengqi Gao
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
27 shared publications - Chunhao Deng
Centre of Reproduction, Development and Aging, Faculty of Health Sciences, University of Macau, Macau SAR, China
27 shared publications - Danyang Wang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
27 shared publications - Guokai Chen
Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau
27 shared publications - Jianeng Zhang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
27 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Clinical characteristics for melanoma cohort analyzed sex difference of survival in patients treated with anti-PD-1 antibody
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Clinical characteristics for melanoma cohort analyzed sex difference of survival in patients treated with anti-PD-1 antibody
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Clinical characteristics for the NSCLC cohort analyzed the correlation between testosterone levels, prognosis and T cell infiltration
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Clinical characteristics for the NSCLC cohort analyzed the correlation between testosterone levels, prognosis and T cell infiltration
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Clinical characteristics for the NSCLC cohort analyzed sex difference of survival in patients treated with anti-PD-1 antibody
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Clinical characteristics for the NSCLC cohort analyzed sex difference of survival in patients treated with anti-PD-1 antibody
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Supplementary Figure 1 and 2 Legends
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Supplementary Figure 1 and 2 Legends
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Sex is known to be an important factor in the incidence, progression, and outcome of cancer. A better understanding of the underlying mechanisms could help improve cancer prevention and treatment. Here, we demonstrated a crucial role of antitumor immunity in the sex differences in cancer. Consistent with observations in human cancers, male mice showed accelerated tumor progression compared with females, but these differences were not observed in immunodeficient mice. Androgen signaling suppressed T-cell immunity against cancer in males. Mechanistically, androgen-activated androgen receptor upregulated expression of USP18, which inhibited TAK1 phosphorylation and the subsequent activation of NF-κB in antitumor T cells. Reduction of testosterone synthesis by surgical castration or using the small-molecular inhibitor abiraterone significantly enhanced the antitumor activity of T cells in male mice and improved the efficacy of anti–PD-1 immunotherapy. Together, this study revealed a novel mechanism contributing to sex differences in cancer. These results indicate that inhibition of androgen signaling is a promising approach to improve the efficacy of immunotherapy in males.Significance:Androgen signaling induces immunosuppression in cancer by blocking T-cell activity through upregulation of USP18 and subsequent inhibition of NF-κB activity, providing a targetable axis to improve antitumor immunity in males.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Sex is known to be an important factor in the incidence, progression, and outcome of cancer. A better understanding of the underlying mechanisms could help improve cancer prevention and treatment. Here, we demonstrated a crucial role of antitumor immunity in the sex differences in cancer. Consistent with observations in human cancers, male mice showed accelerated tumor progression compared with females, but these differences were not observed in immunodeficient mice. Androgen signaling suppressed T-cell immunity against cancer in males. Mechanistically, androgen-activated androgen receptor upregulated expression of USP18, which inhibited TAK1 phosphorylation and the subsequent activation of NF-κB in antitumor T cells. Reduction of testosterone synthesis by surgical castration or using the small-molecular inhibitor abiraterone significantly enhanced the antitumor activity of T cells in male mice and improved the efficacy of anti–PD-1 immunotherapy. Together, this study revealed a novel mechanism contributing to sex differences in cancer. These results indicate that inhibition of androgen signaling is a promising approach to improve the efficacy of immunotherapy in males.Significance:Androgen signaling induces immunosuppression in cancer by blocking T-cell activity through upregulation of USP18 and subsequent inhibition of NF-κB activity, providing a targetable axis to improve antitumor immunity in males.
- Open Access
- 15 August 2025
- Published by Wiley in Cancer Science
- Vol. 116 (11) , 3125-3138
Comparison of the Efficacy of Different First‐Line Therapies for EGFR L858R ‐Mutated NSCLC Patients With Brain Metastases
Compared to exon 19 deletions, the epidermal growth factor receptor (EGFR) exon 21 L858R (21L858R) mutation is associated with a poorer prognosis in non‐small cell lung cancer (NSCLC), particularly in patients with brain metastases (BMs). However, there is a notable lack of prospective or retrospective clinical studies focusing on this specific population. This study aims to evaluate the efficacy of different first‐line treatment strategies using EGFR‐tyrosine kinase inhibitors (TKIs) in NSCLC patients harboring the 21L858R mutation and BMs while providing insights into concurrent mutations and resistance mechanisms. We analyzed clinical data from 331 patients diagnosed with the EGFR 21L858R mutation and BMs who received first‐line EGFR‐TKI treatment at Sun Yat‐sen University Cancer Center between April 2014 and June 2023 (ID: GASTO‐1027). The efficacy was evaluated through intracranial progression‐free survival (iPFS), PFS, and overall survival (OS). Compared to the first‐generation and second‐generation cohorts, the third‐generation EGFR‐TKI cohort demonstrated significant improvements in iPFS ( p = 0.002), PFS ( p < 0.001), and OS ( p = 0.016). Within the third‐generation EGFR‐TKI group, the combination chemotherapy cohort exhibited the most favorable outcomes, with marked extensions in both iPFS ( p = 0.037) and PFS ( p = 0.049). Multivariate analyses identified the treatment regimen of third‐generation TKIs combined with chemotherapy as an independent prognostic factor for improved iPFS. Compared to treatment regimens containing first‐generation or second‐generation EGFR‐TKIs, patients with TP53 mutations derived greater benefit from treatment regimens containing third‐generation EGFR‐TKIs. The combination of third‐generation EGFR‐TKIs with chemotherapy shows enhanced efficacy in patients with EGFR 21L858R mutations and BMs compared to other treatments. Future prospective clinical trials are essential to assess this combination's effects in this population.
- 15 August 2025
- Published by Wiley in Cancer Science
- Vol. 116 (11) , 3125-3138
Open AccessComparison of the Efficacy of Different First‐Line Therapies for EGFR L858R ‐Mutated NSCLC Patients With Brain Metastases
Compared to exon 19 deletions, the epidermal growth factor receptor (EGFR) exon 21 L858R (21L858R) mutation is associated with a poorer prognosis in non‐small cell lung cancer (NSCLC), particularly in patients with brain metastases (BMs). However, there is a notable lack of prospective or retrospective clinical studies focusing on this specific population. This study aims to evaluate the efficacy of different first‐line treatment strategies using EGFR‐tyrosine kinase inhibitors (TKIs) in NSCLC patients harboring the 21L858R mutation and BMs while providing insights into concurrent mutations and resistance mechanisms. We analyzed clinical data from 331 patients diagnosed with the EGFR 21L858R mutation and BMs who received first‐line EGFR‐TKI treatment at Sun Yat‐sen University Cancer Center between April 2014 and June 2023 (ID: GASTO‐1027). The efficacy was evaluated through intracranial progression‐free survival (iPFS), PFS, and overall survival (OS). Compared to the first‐generation and second‐generation cohorts, the third‐generation EGFR‐TKI cohort demonstrated significant improvements in iPFS ( p = 0.002), PFS ( p < 0.001), and OS ( p = 0.016). Within the third‐generation EGFR‐TKI group, the combination chemotherapy cohort exhibited the most favorable outcomes, with marked extensions in both iPFS ( p = 0.037) and PFS ( p = 0.049). Multivariate analyses identified the treatment regimen of third‐generation TKIs combined with chemotherapy as an independent prognostic factor for improved iPFS. Compared to treatment regimens containing first‐generation or second‐generation EGFR‐TKIs, patients with TP53 mutations derived greater benefit from treatment regimens containing third‐generation EGFR‐TKIs. The combination of third‐generation EGFR‐TKIs with chemotherapy shows enhanced efficacy in patients with EGFR 21L858R mutations and BMs compared to other treatments. Future prospective clinical trials are essential to assess this combination's effects in this population.